{"id":"W3088717396","doi":"10.1080/21678421.2020.1822410","title":"A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS","year":2020,"lang":"nl","type":"article","venue":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Saskatchewan; University of Alberta; Université Laval; University of Toronto; Montreal Neurological Institute and Hospital","funders":"National Center for Advancing Translational Sciences; Cytokinetics; CA Technologies; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma US","keywords":"Medicine; Placebo; Internal medicine; Tolerability; Statistical significance; Clinical endpoint; Nausea; Discontinuation; Adverse effect; Renal function; Dose-ranging study; Amyotrophic lateral sclerosis; Randomized controlled trial; Double blind","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00159781,0.001950875,0.00197528,0.0003414306,0.0006044328,0.001067487,0.0009254483,0.002238867,0.01480545],"category_scores_gemma":[0.001350199,0.0005597325,0.001322394,0.0002749484,0.0009056057,0.001108143,0.0003168441,0.003300847,0.002230426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006176805,"about_ca_system_score_gemma":0.001315576,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008127921,"about_ca_topic_score_gemma":0.003141542,"domain_scores_codex":[0.9995944,0.0002084633,0.0000242534,0.00007106859,0.00002829897,0.00007355476],"domain_scores_gemma":[0.9994113,0.0001299174,0.000135776,0.000039426,0.00004878011,0.0002348221],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9503105,0.01064117,0.0004500223,0.001221515,0.0007472161,0.0000503183,0.0000708022,0.0003184721,0.005762104,0.0003187632,0.005919882,0.0241893],"study_design_scores_gemma":[0.9641581,0.03372046,0.0005179835,0.00004201382,0.0001233041,0.00002063311,0.00001146108,0.00013382,0.0002443915,0.0001343663,0.0008848416,0.000008691317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9401299,0.009711019,0.001751415,0.003462633,0.00239618,0.02136314,0.004975774,0.0005567392,0.01565322],"genre_scores_gemma":[0.9416423,0.005900175,0.005736157,0.007156892,0.001191637,0.01995657,0.004952787,0.0001002998,0.01336323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01480545,"threshold_uncertainty_score":0.04952914,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06039995687883074,"score_gpt":0.2916062694905002,"score_spread":0.2312063126116695,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}